Your browser doesn't support javascript.
loading
A Nationwide Retrospective Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Adult Hemophagocytic Lymphohistiocytosis.
Kim, Haryoon; Mizuno, Kota; Masuda, Kyoko; Sakurai, Masatoshi; Ara, Takahide; Naito, Kensuke; Uehara, Yasufumi; Yamamoto, Go; Osada, Makoto; Machida, Shinichiro; Horio, Tomohiro; Fukushima, Kentaro; Mori, Yasuo; Ichinohe, Tatsuo; Fukuda, Takahiro; Atsuta, Yoshiko; Kataoka, Keisuke.
Affiliation
  • Kim H; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
  • Mizuno K; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
  • Masuda K; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Sakurai M; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Ara T; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.
  • Naito K; Department of Hematology, Hamamatsu Medical Center, Hamamatsu, Japan.
  • Uehara Y; Department of Hematology, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
  • Yamamoto G; Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
  • Osada M; Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
  • Machida S; Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan.
  • Horio T; Division of Hematology, Department of Internal Medicine, Aichi Medical University Hospital, Nagakute, Japan.
  • Fukushima K; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Mori Y; Hematology, Oncology & Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Ichinohe T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
  • Fukuda T; Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
  • Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan.
  • Kataoka K; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan. Electronic address: kkataoka-tky@umin.ac.jp.
Transplant Cell Ther ; 30(4): 419.e1-419.e12, 2024 Apr.
Article in En | MEDLINE | ID: mdl-38266963
ABSTRACT
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening disorder characterized by systemic hyperinflammation. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative treatment for primary and relapsed/refractory HLH, the optimal strategy has not been established. We retrospectively analyzed 56 adult patients (≥18 years) with primary and secondary HLH (mainly consisting of Epstein-Barr virus-associated HLH) who underwent allo-HSCT using the registry database of the Japanese Society for Transplantation and Cellular Therapy, including 26 patients who underwent cord blood transplantation (CBT). One-fourth of patients received myeloablative conditioning (MAC), mainly consisting of total body irradiation-based regimens. The 3-year overall survival (OS) was 40.6%, while the 3-year cumulative incidences of relapse and non-relapse mortality (NRM) were 19.8% and 39.6%, respectively. In univariable analysis, age at allo-HSCT (the 3-year OS 27.5% for ≥ 25 years old vs 58.0% for < 25 years old, P = .025), conditioning intensity (7.1% for MAC vs 51.8% for reduced-intensity conditioning (RIC), P = .002), and donor source (26.0% for CBT vs 52.9% for bone marrow or peripheral blood stem cell transplantation (BMT/PBSCT), P = .030) were associated with significantly inferior OS. In multivariable analysis, older age at allo-HSCT (≥ 25 years old) (Hazard ratio [HR], 2.37; 95% CI, 1.01 to 5.58; P = .048), MAC (HR, 2.45; 95% CI, 1.09 to 5.53; P = .031), and CBT (HR, 2.21; 95% CI, 1.04 to 4.71; P = .040) were independently associated with worse OS. In addition, only conditioning intensity predicted higher NRM (the 3-year NRM 78.6% for MAC vs 26.6% for RIC), while no factors were associated with the relapse rate. This study includes the largest number of adult HLH patients undergoing CBT. Although the use of CBT is acceptable, BMT/PBSCT are more favorable strategies in allo-HSCT in adult HLH. Regarding conditioning intensity, RIC regimens are more beneficial in this setting.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Epstein-Barr Virus Infections / Lymphohistiocytosis, Hemophagocytic Type of study: Prognostic_studies / Risk_factors_studies Limits: Adult / Child, preschool / Humans Language: En Journal: Transplant Cell Ther Year: 2024 Document type: Article Affiliation country: Japan

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematopoietic Stem Cell Transplantation / Epstein-Barr Virus Infections / Lymphohistiocytosis, Hemophagocytic Type of study: Prognostic_studies / Risk_factors_studies Limits: Adult / Child, preschool / Humans Language: En Journal: Transplant Cell Ther Year: 2024 Document type: Article Affiliation country: Japan